Table 1.
Sample cohort | Cases (n) | Controls (n) | Beta | P | P* |
Initial | 1,040 | 1,058 | 428 | 5.0 × 10−13 | 6.9 × 10−21 |
Validation | 7,603 | 6,170 | 182 | 7.1 × 10−12 | 2.3 × 10−22 |
Whole | 8,746 | 7,228 | 213 | 4.2 × 10−27 | 3.5 × 10−36 |
Pre-MS | 476 | 478 | −80 | 0.42 | 0.23 |
RA | 986 | 689 | −2 | 0.95 | 0.38 |
IIM | 219 | 306** | 4 | 0.79 | 0.81 |
SLE | 349 | 306** | −2 | 0.85 | 0.36 |
Association analyses were adjusted for age, sex, and EBNA1 status. Analyses were also adjusted for study type for the validation and whole cohorts. *Log10 transformed signal intensities. **Same control set (selected to match SLE cases) were used for both IIM and SLE cohorts. MS, multiple sclerosis; RA, rheumatoid arthritis; IIM, idiopathic inflammatory myopathy; SLE, systemic lupus erythematosus.